Telomir Pharmaceuticals, Common Stock Net Income
| TELO Stock | 4.91 0.03 0.61% |
Telomir Pharmaceuticals, Common fundamentals help investors to digest information that contributes to Telomir Pharmaceuticals,'s financial success or failures. It also enables traders to predict the movement of Telomir Stock. The fundamental analysis module provides a way to measure Telomir Pharmaceuticals,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telomir Pharmaceuticals, stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.8 M | -11.2 M | |
| Net Loss | -11.8 M | -11.2 M | |
| Net Loss | (0.44) | (0.42) |
Telomir | Net Income |
Telomir Pharmaceuticals, Common Company Net Income Analysis
Telomir Pharmaceuticals,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Telomir Pharmaceuticals, Net Income | (13.07 M) |
Most of Telomir Pharmaceuticals,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telomir Pharmaceuticals, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Telomir Pharmaceuticals, Common reported net income of (13.07 Million). This is 103.83% lower than that of the Pharmaceuticals sector and 118.66% lower than that of the Health Care industry. The net income for all United States stocks is 102.29% higher than that of the company.
Telomir Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telomir Pharmaceuticals,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telomir Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Telomir Pharmaceuticals, by comparing valuation metrics of similar companies.Telomir Pharmaceuticals, is currently under evaluation in net income category among its peers.
Telomir Pharmaceuticals, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Telomir Pharmaceuticals,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Telomir Pharmaceuticals,'s managers, analysts, and investors.Environmental | Governance | Social |
Telomir Fundamentals
| Return On Equity | -17.53 | ||||
| Return On Asset | -2.05 | ||||
| Current Valuation | 147.08 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Shares Owned By Insiders | 42.66 % | ||||
| Shares Owned By Institutions | 6.90 % | ||||
| Number Of Shares Shorted | 650.6 K | ||||
| Price To Book | 332.47 X | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (13.07 M) | ||||
| Total Debt | 101 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (3.86 M) | ||||
| Short Ratio | 5.77 X | ||||
| Earnings Per Share | (0.78) X | ||||
| Target Price | 12.15 | ||||
| Market Capitalization | 146.98 M | ||||
| Total Asset | 4.77 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | (900.34 K) | ||||
| Net Asset | 4.77 M |
About Telomir Pharmaceuticals, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telomir Pharmaceuticals, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telomir Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telomir Pharmaceuticals, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Telomir Pharmaceuticals,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Moving against Telomir Stock
| 0.64 | ALVO | Alvotech | PairCorr |
| 0.57 | BMY | Bristol Myers Squibb | PairCorr |
| 0.56 | GILD | Gilead Sciences | PairCorr |
| 0.46 | XAIR | Beyond Air | PairCorr |
| 0.39 | CAH | Cardinal Health | PairCorr |
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Telomir Pharmaceuticals, Piotroski F Score and Telomir Pharmaceuticals, Altman Z Score analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.